{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:39:19Z","timestamp":1772138359007,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T00:00:00Z","timestamp":1640563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Guangdong Emergency Program for Prevention and Control of COVID-19","award":["2020A1111340002"],"award-info":[{"award-number":["2020A1111340002"]}]},{"name":"Shenzhen Key Research Project for Prevention and Control of COVID-19"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic needs effective vaccines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a phase 2 randomized, double-blind, placebo-controlled trial, 500 adults aged 18\u201359 years or \u226560 years were randomized in 2:2:1 ratio to receive 3 doses of 5 \u03bcg or 10 \u03bcg of a SARS-CoV-2 inactivated vaccine, or placebo separated by 28 days. Adverse events (AEs) were recorded through day 28 after each dosing. Live virus or pseudovirus neutralizing antibodies, and receptor binding domain immunoglobulin G (RBD-IgG) antibody were tested after the second and third doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two doses of the vaccine elicited geometric mean titers (GMTs) of 102\u2013119, 170\u2013176, and 1449\u20131617 for the 3 antibodies in younger adults. Pseudovirus neutralizing and RBD-IgG GMTs were similar between older and younger adults. The third dose slightly (&amp;lt;1.5 fold) increased GMTs. Seroconversion percentages were 94% or more after 2 doses, which were generally similar after 3 doses. The predominant AEs were injection-site pain. All the AEs were grade 1 or 2 in intensity. No serious AE was deemed related to study vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Two doses of this vaccine induced robust immune response and had good safety profile. A third dose given 28 days after the second dose elicited limited boosting antibody response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiab627","type":"journal-article","created":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T07:13:00Z","timestamp":1640589180000},"page":"1701-1709","source":"Crossref","is-referenced-by-count":12,"title":["Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial"],"prefix":"10.1093","volume":"225","author":[{"given":"Jiankai","family":"Liu","sequence":"first","affiliation":[{"name":"Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoying","family":"Huang","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guifan","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biotechnology Co., Ltd., Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianyun","family":"Chang","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biotechnology Co., Ltd., Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Minhai Biotechnology Co., Ltd., Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Chu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialei","family":"Hu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao","family":"Deng","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Huaiyin District Center for Disease Control and Prevention, Huai\u2019an, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingliang","family":"Wu","sequence":"additional","affiliation":[{"name":"Huaiyin District Center for Disease Control and Prevention, Huai\u2019an, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Huang","sequence":"additional","affiliation":[{"name":"National Institutes for Food and Drug Control, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxing","family":"Pan","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Tan","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,27]]},"reference":[{"key":"2022051716042507500_CIT0001","author":"World Health Organization."},{"key":"2022051716042507500_CIT0002","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2022051716042507500_CIT0003","author":"World"},{"key":"2022051716042507500_CIT0004","author":"UNICEF."},{"key":"2022051716042507500_CIT0005","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2022051716042507500_CIT0006","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2020.15543","article-title":"Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials.","volume":"324","author":"Xia","year":"2020","journal-title":"JAMA"},{"key":"2022051716042507500_CIT0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial.","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022051716042507500_CIT0008","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial.","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"key":"2022051716042507500_CIT0009","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2\u2014preliminary report.","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"2022051716042507500_CIT0010","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"2022051716042507500_CIT0011","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia.","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"2022051716042507500_CIT0012","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 Covid-19 vaccine.","volume":"385","author":"Heath","year":"2021","journal-title":"N Engl J Med"},{"key":"2022051716042507500_CIT0013","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/CM9.0000000000001573","article-title":"Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials.","volume":"134","author":"Pan","year":"2021","journal-title":"Chinese Med J"},{"key":"2022051716042507500_CIT0014","first-page":"S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.","author":"Zeng","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022051716042507500_CIT0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.","volume":"398","author":"Shrotri","year":"2021","journal-title":"Lancet"},{"key":"2022051716042507500_CIT0016","author":"National Medical Products Administration.","year":"2019"},{"key":"2022051716042507500_CIT0017","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2022051716042507500_CIT0018","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review.","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"},{"key":"2022051716042507500_CIT0019","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40249-021-00878-5","article-title":"Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials.","volume":"10","author":"Chen","year":"2021","journal-title":"Infect Dis Poverty"},{"key":"2022051716042507500_CIT0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/vaccines9090989","article-title":"Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of different vaccines at phase 3.","volume":"9","author":"Fan","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2022051716042507500_CIT0021","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"2022051716042507500_CIT0022","first-page":"CD013479","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.","volume":"11","author":"Bergman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2022051716042507500_CIT0023","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.vaccine.2015.02.058","article-title":"Antibody responses among adolescent females receiving the quadrivalent HPV vaccine series corresponding to standard or non-standard dosing intervals.","volume":"33","author":"Russell","year":"2015","journal-title":"Vaccine"},{"key":"2022051716042507500_CIT0024","doi-asserted-by":"crossref","first-page":"100133","DOI":"10.1016\/j.lanwpc.2021.100133","article-title":"Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: an open-label, randomized, controlled trial.","volume":"10","author":"Wang","year":"2021","journal-title":"Lancet Reg Health West Pac"},{"key":"2022051716042507500_CIT0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0168-8278(97)80039-6","article-title":"Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults.","volume":"26","author":"Chen","year":"1997","journal-title":"J Hepatol"},{"key":"2022051716042507500_CIT0026","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2021.09.078","article-title":"Antibody response to the inactivated SARS-CoV-2 vaccine among healthcare workers, Indonesia.","volume":"113","author":"Cucunawangsih","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2022051716042507500_CIT0027","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates.","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiab627\/42418071\/jiab627.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/10\/1701\/43712447\/jiab627.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/10\/1701\/43712447\/jiab627.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T15:09:51Z","timestamp":1652800191000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/10\/1701\/6484920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,27]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,12,27]]},"published-print":{"date-parts":[[2022,5,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiab627","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.07.21253850","asserted-by":"object"}]},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,15]]},"published":{"date-parts":[[2021,12,27]]}}}